Your browser doesn't support javascript.
loading
The MOPEAD project: Advancing patient engagement for the detection of "hidden" undiagnosed cases of Alzheimer's disease in the community.
Rodríguez-Gómez, Octavio; Rodrigo, Adrián; Iradier, Fátima; Santos-Santos, Miguel A; Hundemer, Hans; Ciudin, Andreea; Sannemann, Lena; Zwan, Marissa; Glaysher, Bridget; Wimo, Anders; Bonn, Jaka; Johansson, Gunilla; Rodriguez, Isabel; Alegret, Montse; Gove, Dianne; Pinó, Susana; Trigueros, Paloma; Kivipelto, Miia; Mathews, Brandy; Ciudad, Antonio; Ferreira, Daniel; Bintener, Christophe; Gurruchaga, Miren; Westman, Eric; Belger, Mark; Valero, Sergi; Maguire, Peggy; Krivec, David; Kramberger, Milica; Simó, Rafael; Garro, Inmaculada Pérez; Visser, Pieter Jelle; Dumas, Annette; Georges, Jean; Jessen, Frank; Winblad, Bengt; Shering, Craig; Stewart, Neil; Campo, Laura; Boada, Mercè.
Affiliation
  • Rodríguez-Gómez O; Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades - Universitat Internacional de Catalunya, Barcelona, Spain; Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Barcelona, Spain. Electronic address: orodriguez
  • Rodrigo A; GMV SECURE E SOLUTIONS, Valencia, Spain.
  • Iradier F; Eli Lilly and Company (Lilly España), Alcobendas, Spain.
  • Santos-Santos MA; Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades - Universitat Internacional de Catalunya, Barcelona, Spain.
  • Hundemer H; Eli Lilly and Company (Lilly Deutschland GmbH), Bad Homburg, Germany.
  • Ciudin A; Vall d'Hebron Research Institute (VHIR) and CIBERDEM (ISCIII), Barcelona, Spain.
  • Sannemann L; Department of Psychiatry, University of Cologne, Cologne, Germany.
  • Zwan M; Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.
  • Glaysher B; Modus Research and Innovation Limited, Dundee, Scotland.
  • Wimo A; Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Sweden.
  • Bonn J; Center for Cognitive Impairments, Department of Neurology, University Medical Center Ljubljana, Ljubljana, Slovenia.
  • Johansson G; Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Sweden.
  • Rodriguez I; Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades - Universitat Internacional de Catalunya, Barcelona, Spain.
  • Alegret M; Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades - Universitat Internacional de Catalunya, Barcelona, Spain; Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Barcelona, Spain.
  • Gove D; Alzheimer Europe, Luxembourg.
  • Pinó S; Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades - Universitat Internacional de Catalunya, Barcelona, Spain.
  • Trigueros P; GMV SECURE E SOLUTIONS, Valencia, Spain.
  • Kivipelto M; Division of Clinical Geriatrics, Centre for Alzheimer Research, Department of Neurobiology, Care Sciences, and Society, Karolinska Institutet, Stockholm, Sweden; Institute of Clinical Medicine/Neurology, University of Eastern Finland, Kuopio, Finland.
  • Mathews B; Eli Lilly and Company, Indianapolis, IN, USA.
  • Ciudad A; Eli Lilly and Company (Lilly España), Alcobendas, Spain.
  • Ferreira D; Division of Clinical Geriatrics, Centre for Alzheimer Research, Department of Neurobiology, Care Sciences, and Society, Karolinska Institutet, Stockholm, Sweden.
  • Bintener C; Alzheimer Europe, Luxembourg.
  • Gurruchaga M; Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades - Universitat Internacional de Catalunya, Barcelona, Spain.
  • Westman E; Division of Clinical Geriatrics, Centre for Alzheimer Research, Department of Neurobiology, Care Sciences, and Society, Karolinska Institutet, Stockholm, Sweden; Department of Neuroimaging, Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology, and Neuroscience, King's College London
  • Belger M; Eli Lilly and Company (Lilly UK), Surrey, UK.
  • Valero S; Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades - Universitat Internacional de Catalunya, Barcelona, Spain; Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Barcelona, Spain.
  • Maguire P; European Institute of Womens Health, Dublin, Ireland.
  • Krivec D; Zdruzenje Spomincica, Ljubljana, Slovenia.
  • Kramberger M; Center for Cognitive Impairments, Department of Neurology, University Medical Center Ljubljana, Ljubljana, Slovenia.
  • Simó R; Vall d'Hebron Research Institute (VHIR) and CIBERDEM (ISCIII), Barcelona, Spain.
  • Garro IP; GMV SECURE E SOLUTIONS, Valencia, Spain.
  • Visser PJ; Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands; Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands.
  • Dumas A; ASDM Consulting, Brussels, Belgium.
  • Georges J; Alzheimer Europe, Luxembourg.
  • Jessen F; Department of Psychiatry, University of Cologne, Cologne, Germany; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
  • Winblad B; Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Sweden; Karolinska Univ Hospital, Theme Aging, Stockholm, Sweden.
  • Shering C; AstraZeneca, Waltham, MA, USA.
  • Stewart N; Modus Research and Innovation Limited, Dundee, Scotland.
  • Campo L; Eli Lilly and Company, Firenze, Italy.
  • Boada M; Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades - Universitat Internacional de Catalunya, Barcelona, Spain; Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Barcelona, Spain.
Alzheimers Dement ; 15(6): 828-839, 2019 06.
Article in En | MEDLINE | ID: mdl-31076376
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Early Diagnosis / Public-Private Sector Partnerships / Alzheimer Disease / Prodromal Symptoms Type of study: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limits: Humans Country/Region as subject: Europa Language: En Journal: Alzheimers Dement Year: 2019 Type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Early Diagnosis / Public-Private Sector Partnerships / Alzheimer Disease / Prodromal Symptoms Type of study: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limits: Humans Country/Region as subject: Europa Language: En Journal: Alzheimers Dement Year: 2019 Type: Article